Patents by Inventor Stephen Baylin
Stephen Baylin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10363264Abstract: The presently disclosed subject matter provides methods to treat cancer cells using low doses of DNA demethylating agents and poly ADP ribose polymerase (PARP) inhibitors. Methods also are provided for sensitizing a cell to a PARP inhibitor.Type: GrantFiled: January 21, 2015Date of Patent: July 30, 2019Assignees: UNIVERSITY OF MARYLAND, BALTIMORE, THE JOHNS HOPKINS UNIVERSITYInventors: Feyruz Rassool, Stephen Baylin, Carine Robert
-
Patent number: 10167513Abstract: The invention provides compositions and methods for detecting a neoplasia (e.g., pancreatic cancer, lung cancer, colon cancer) in a subject sample (e.g., serum, blood, plasma, tissue). In particular embodiments, the invention provides methods for detecting BNC1 and ADAMTS1 promoter methylation in circulating DNA in serum.Type: GrantFiled: May 25, 2011Date of Patent: January 1, 2019Assignee: The Johns Hopkins UniversityInventors: Nita Ahuja, Stephen Baylin, James G. Herman, Jeff Wang, Vasudev Bailey, Mi J. Yi
-
Patent number: 10105383Abstract: The presently disclosed subject matter provides methods to treat cancer cells using low doses of DNA demethylating agents and poly ADP ribose polymerase (PARP) inhibitors. Methods also are provided for sensitizing a cell to a PARP inhibitor.Type: GrantFiled: September 1, 2016Date of Patent: October 23, 2018Assignees: UNIVERSITY OF MARYLAND, BALTIMORE, THE JOHNS HOPKINS UNIVERSITYInventors: Feyruz Rassool, Stephen Baylin, Carine Robert, Khadiza Chowdhury, Nidal Muvarak
-
Patent number: 10105382Abstract: The presently disclosed subject matter provides methods to treat cancer cells using low doses of DNA demethylating agents and poly ADP ribose polymerase (PARP) inhibitors. Methods also are provided for sensitizing a cell to a PARP inhibitor.Type: GrantFiled: September 1, 2016Date of Patent: October 23, 2018Assignees: UNIVERSITY OF MARYLAND, BALTIMORE, THE JOHNS HOPKINS UNIVERSITYInventors: Feyruz Rassool, Stephen Baylin, Carine Robert, Khadiza Chowdhury, Nidal Muvarak
-
Publication number: 20170121775Abstract: Methods and tools are provided for detecting and predicting lung cancer. The methods and tools are based on epigenetic modification due to methylation of genes in lung cancer or pre-lung cancer. The tools can be assembled into kits or can be used separately. Genes found to be epigenetically silenced in association with lung cancer include ACSL6, ALS2CL, APC2, ARTS-1, BEX1, BMP7, BNIP3, CBR3, CD248, CD44, CHD5, DLK1, DPYSL4, DSC2, EDNRB, EPB41L3, EPHB6, ERBB3, FBLN2, FBN2, FOXL2, GNAS, GSTP1, HS3ST2, HPN, IGFBP7, IRF7, JAM3, LOX, LY6D, LY6K, MACF1, MCAM, NCBP1, NEFH, NID2, PCDHB15, PCDHGA12, PFKP, PGRMC1, PHACTR3, PHKA2, POMC, PRKCA, PSEN1, RASSF1A, RASSF2, RBP1, RRAD, SFRP1, SGK, SOD3, SOX17, SULF2, TIMP3, TJP2, TRPV2, UCHL1, WDR69, ZFP42, ZNF442, and ZNF655.Type: ApplicationFiled: February 9, 2016Publication date: May 4, 2017Applicants: MDxHealth, THE JOHNS HOPKINS UNIVERSITYInventors: Wim VAN CRIEKINGE, Josef STRAUB, Geert TROOSKENS, Stephen BAYLIN, James HERMAN, Kornel SCHUEBEL, Leslie COPE, Leander VAN NESTE
-
Publication number: 20160367582Abstract: The presently disclosed subject matter provides methods to treat cancer cells using low doses of DNA demethylating agents and poly ADP ribose polymerase (PARP) inhibitors. Methods also are provided for sensitizing a cell to a PARP inhibitor.Type: ApplicationFiled: September 1, 2016Publication date: December 22, 2016Applicants: THE JOHNS HOPKINS UNIVERSITY, UNIVERSITY OF MARYLAND, BALTIMOREInventors: Feyruz RASSOOL, Stephen BAYLIN, Carine ROBERT, Khadiza Chowdhury, Nidal Muvarak
-
Publication number: 20160367581Abstract: The presently disclosed subject matter provides methods to treat cancer cells using low doses of DNA demethylating agents and poly ADP ribose polymerase (PARP) inhibitors. Methods also are provided for sensitizing a cell to a PARP inhibitor.Type: ApplicationFiled: September 1, 2016Publication date: December 22, 2016Applicants: THE JOHNS HOPKINS UNIVERSITY, UNIVERSITY OF MARYLAND, BALTIMOREInventors: Feyruz RASSOOL, Stephen BAYLIN, Carine ROBERT, Khadiza Chowdhury, Nidal Muvarak
-
Publication number: 20160346306Abstract: The presently disclosed subject matter provides methods to treat cancer cells using low doses of DNA demethylating agents and poly ADP ribose polymerase (PARP) inhibitors. Methods also are provided for sensitizing a cell to a PARP inhibitor.Type: ApplicationFiled: January 21, 2015Publication date: December 1, 2016Applicants: THE JOHNS HOPKINS UNIVERSITY, University of Maryland, BaltimoreInventors: Feyruz RASSOOL, Stephen BAYLIN, Carine ROBERT
-
Publication number: 20130288241Abstract: The invention provides compositions and methods for detecting a neoplasia (e.g., pancreatic cancer, lung cancer, colon cancer) in a subject sample (e.g., serum, blood, plasma, tissue). In particular embodiments, the invention provides methods for detecting BNC1 and ADAMTS1 promoter methylation in circulating DNA in serum.Type: ApplicationFiled: May 25, 2011Publication date: October 31, 2013Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Nita Ahuja, Stephen Baylin, James G. Herman, Jeff Wang, Vasudev Bailey, Mi J. Yi
-
Patent number: 8133986Abstract: The present invention provides a method for identifying a methylated CpG containing nucleic acid by contacting a nucleic acid with a methylation sensitive restriction endonuclease that cleaves unmethylated PcG sites and contacting the sample with an isoschizomer of the methylation sensitive restriction endonuclease, which cleaves both methylated and unmethylated CpG sites. The method also includes amplification of the CpG-containing nucleic acid using CpG-specific oligonucleotide primers. A method is also provided for detecting an age associated disorder by identification of a methylated CpG containing nucleic acid. A method is further provided for evaluating the responses of a cell to an agent. A kit is useful for detection of a CpG containing nucleic acid is also provided. Nucleic acid sequences encoding novel methylated clones.Type: GrantFiled: April 20, 2010Date of Patent: March 13, 2012Assignee: The Johns Hopkins University School of MedicineInventors: Jean-Pierre Issa, Stephen Baylin, Minoru Toyota
-
Publication number: 20110165565Abstract: The present invention features methods and compositions for methylation detection, as well as a novel method for polynucleotide extraction and sodium bisulfite treatment.Type: ApplicationFiled: January 5, 2009Publication date: July 7, 2011Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Tza-Huei Wang, Stephen Baylin, James Gordon Herman, Vasudev Bailey, Hariharan Easwaran, Hetty Carraway, Yi Zhang, Brian P. Keeley
-
Publication number: 20110117551Abstract: Methods and tools are provided for detecting and predicting lung cancer. The methods and tools are based on epigenetic modification due to methylation of genes in lung cancer or pre-lung cancer. The tools can be assembled into kits or can be used seperately. Genes found to be epigentically silenced in association with lung cancer include ACSL6, ALS2CL, APC2, ART-S1, BEX1, BMP7, BNIP3, CBR3, CD248, CD44, CHD5, DLK1, DPYSL4, DSC2, EDNRB, EPB41L3, EPHB6, ERBB3, FBLN2, FBN2, FOXL2, GNAS, GSTP1, HS3ST2, HPN, IGFBP7, IRF7, JAM3, LOX, LY6D, LY6K, MACF1, MCAM, NCBP1, NEFH, NID2, PCDHB15, PCDHGA12, PFKP, PGRMC1, PHACTR3, PHKA2, POMC, PRKCA, PSEN1, RASSF1A, RASSF2, RBP1, RRAD, SFRP1, SGK, SOD3, SOX17, SULF2, TIMP3, TJP2, TRPV2, UCHL1, WDR69, ZFP42, ZNF442, and ZNF655.Type: ApplicationFiled: February 19, 2009Publication date: May 19, 2011Applicants: ONCOMETHYLOME SCIENCES SA, THE JOHNS HOPKINS UNIVERSITYInventors: Wim Van Criekinge, Josef Straub, Geert Trooskens, Stephen Baylin, James Herman, Kornel Schuebel, Leslie Cope, Leander Van Neste
-
Publication number: 20110104177Abstract: The invention relates to histone deacetylase (HDAC) inhibitors to treat proliferative diseases. The present invention provides novel class III histone deacetylase inhibitors, in particular SIRT1 inhibitors, to reverse the silencing of hypermethylated genes, in combination with one or more other agents, in proliferative diseases such as cancer. The present invention provides methods of activating genes that are silenced by methylation in a subject by administering a HDAC inhibitor in combination with one or more agents.Type: ApplicationFiled: December 28, 2007Publication date: May 5, 2011Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Stephen Baylin, Kevin Pruitt
-
Publication number: 20110020807Abstract: The present invention provides a method for identifying a methylated CpG containing nucleic acid by contacting a nucleic acid with a methylation sensitive restriction endonuclease that cleaves unmethylated PcG sites and contacting the sample with an isoschizomer of the methylation sensitive restriction endonuclease, which cleaves both methylated and unmethylated CpG sites. The method also includes amplification of the CpG-containing nucleic acid using CpG-specific oligonucleotide primers. A method is also provided for detecting an age associated disorder by identification of a methylated CpG containing nucleic acid. A method is further provided for evaluating the responses of a cell to an agent. A kit is useful for detection of a CpG containing nucleic acid is also provided. Nucleic acid sequences encoding novel methylated clones.Type: ApplicationFiled: April 20, 2010Publication date: January 27, 2011Inventors: JEAN-PIERRE ISSA, STEPHEN BAYLIN, MINORU TOYOTA
-
Publication number: 20100278772Abstract: The present invention provides methods for identifying metastases by detecting nucleic acid hypermethylation of one or more genes in one or more samples, and in particular in the lymph nodes. The invention further relates to DNA methylation as a predictor of disease recurrence and patient prognosis, specifically in the field of cancer biology.Type: ApplicationFiled: November 20, 2007Publication date: November 4, 2010Applicant: The Johns Hopkins UniversityInventors: Malcolm V. Brock, Stephen Baylin, James Gordon Herman
-
Patent number: 7700324Abstract: The present invention provides a method for identifying a methylated CpG containing nucleic acid by contacting a nucleic acid with a methylation sensitive restriction endonuclease that cleaves unmethylated CpG sites and contacting the sample with an isoschizomer of the methylation sensitive restriction endonuclease, which cleaves both methylated and unmethylated CpG sites. The method also includes amplification of the CpG-containing nucleic acid using CpG-specific oligonucleotide primers A method is also provided for detecting an age associated disorder by identification of a methylated CpG containing nucleic acid. A method is further provided for evaluation the response of a cell to an agent A kit useful for detection of a CpG containing nucleic acid is also provided. Nucleic acid sequences encoding novel methylated clones.Type: GrantFiled: May 10, 1999Date of Patent: April 20, 2010Assignee: The Johns Hopkins University School of MedicineInventors: Jean-Pierre Issa, Stephen Baylin, Minoru Toyota
-
Publication number: 20080085867Abstract: A genome wide microarray gene expression approach for human colorectal cancer cells was used to identify hundreds of hypermethylated genes for colon cancer. We compared isogenic cells altered pharmacologically versus genetically to induce genomic demethylation, to pinpoint genes activated by DNA demethylation, but not by inhibition of class I and II histone deacetylases (HDACs). We achieve an 82% success rate in predicting genes with densely hypermethylated CpG islands and complete gene silencing. The genes are similarly hypermethylated in primary tumors and have previously undetected tumor suppressor functions. The genes can be used diagnostically to detect cancer, pre-cancer, and likelihood of developing cancer.Type: ApplicationFiled: July 16, 2007Publication date: April 10, 2008Applicants: The Johns Hopkins University, Onomethylome Sciences, S.A.Inventors: Stephen Baylin, Wim van Criekinge, Kornel Schuebel, Leslie Cope, Hiromu Suzuki, James Herman